Do analysts rate RFL or TAOX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, RFL or TAOX?

Synaptogenix has lower revenue, but higher earnings than Rafael. Rafael is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rafael $920K 113.44 -$30.52M -$0.68 N/A Synaptogenix $300K 85.66 -$28.74M -$13.28 N/A

Is RFL or TAOX more profitable?

Synaptogenix has a net margin of -2,153.97% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat Synaptogenix's return on equity. Company Net Margins Return on Equity Return on Assets Rafael -3,321.74% -41.27% -35.32% Synaptogenix -2,153.97% -116.74% -93.67%

Do analysts rate ICCC or TAOX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, ICCC or TAOX?

ImmuCell has higher revenue and earnings than Synaptogenix. ImmuCell is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmuCell $27.64M 3.29 -$1.04M -$0.06 N/A Synaptogenix $300K 85.66 -$28.74M -$13.28 N/A

Is ICCC or TAOX more profitable?

ImmuCell has a net margin of 2.57% compared to Synaptogenix's net margin of -2,153.97%. ImmuCell's return on equity of 2.75% beat Synaptogenix's return on equity. Company Net Margins Return on Equity Return on Assets ImmuCell 2.57% 2.75% 1.79% Synaptogenix -2,153.97% -116.74% -93.67%

Do analysts rate HRTX or TAOX?

Heron Therapeutics presently has a consensus price target of $2.00, suggesting a potential upside of 494.00%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Heron Therapeutics is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heron Therapeutics 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer ALDX or TAOX?

Aldeyra Therapeutics presently has a consensus price target of $5.50, indicating a potential upside of 252.56%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Aldeyra Therapeutics is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aldeyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Synaptogenix (TAOX) Competitors

$3.44 -0.04 (-1.15%)

Closing price 04:00 PM Eastern

Extended Trading

$3.46 +0.02 (+0.58%)

As of 07:34 PM Eastern

Compare

TAOX vs. RFL, ICCC, HRTX, ALDX, and VRCA

Should you buy Synaptogenix stock or one of its competitors? Synaptogenix's main competitors and comparable companies include Rafael (RFL), ImmuCell (ICCC), Heron Therapeutics (HRTX), Aldeyra Therapeutics (ALDX), and Verrica Pharmaceuticals (VRCA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Synaptogenix compare to Rafael?

Rafael (NYSE:RFL) and Synaptogenix (NASDAQ:TAOX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

In the previous week, Synaptogenix had 2 more articles in the media than Rafael. MarketBeat recorded 2 mentions for Synaptogenix and 0 mentions for Rafael. Synaptogenix's average media sentiment score of 1.63 beat Rafael's score of 0.00 indicating that Synaptogenix is being referred to more favorably in the news media.

Company	Overall Sentiment
Rafael	Neutral
Synaptogenix	Very Positive

11.3% of Rafael shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 32.9% of Rafael shares are owned by insiders. Comparatively, 2.7% of Synaptogenix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Synaptogenix has lower revenue, but higher earnings than Rafael. Rafael is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rafael	$920K	113.44	-$30.52M	-$0.68	N/A
Synaptogenix	$300K	85.66	-$28.74M	-$13.28	N/A

Rafael has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Synaptogenix has a net margin of -2,153.97% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rafael	-3,321.74%	-41.27%	-35.32%
Synaptogenix	-2,153.97%	-116.74%	-93.67%

Summary

Rafael beats Synaptogenix on 7 of the 13 factors compared between the two stocks.

How does Synaptogenix compare to ImmuCell?

ImmuCell (NASDAQ:ICCC) and Synaptogenix (NASDAQ:TAOX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

ImmuCell has higher revenue and earnings than Synaptogenix. ImmuCell is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.29	-$1.04M	-$0.06	N/A
Synaptogenix	$300K	85.66	-$28.74M	-$13.28	N/A

13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by company insiders. Comparatively, 2.7% of Synaptogenix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ImmuCell has a net margin of 2.57% compared to Synaptogenix's net margin of -2,153.97%. ImmuCell's return on equity of 2.75% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	2.57%	2.75%	1.79%
Synaptogenix	-2,153.97%	-116.74%	-93.67%

ImmuCell has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, ImmuCell had 6 more articles in the media than Synaptogenix. MarketBeat recorded 8 mentions for ImmuCell and 2 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 1.63 beat ImmuCell's score of 0.58 indicating that Synaptogenix is being referred to more favorably in the news media.

Company	Overall Sentiment
ImmuCell	Positive
Synaptogenix	Very Positive

Summary

ImmuCell beats Synaptogenix on 10 of the 13 factors compared between the two stocks.

How does Synaptogenix compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Synaptogenix (NASDAQ:TAOX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

Heron Therapeutics has higher revenue and earnings than Synaptogenix. Heron Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.41	-$20.19M	-$0.19	N/A
Synaptogenix	$300K	85.66	-$28.74M	-$13.28	N/A

In the previous week, Heron Therapeutics had 19 more articles in the media than Synaptogenix. MarketBeat recorded 21 mentions for Heron Therapeutics and 2 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 1.63 beat Heron Therapeutics' score of -0.36 indicating that Synaptogenix is being referred to more favorably in the news media.

Company	Overall Sentiment
Heron Therapeutics	Neutral
Synaptogenix	Very Positive

Heron Therapeutics presently has a consensus price target of $2.00, suggesting a potential upside of 494.00%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Heron Therapeutics is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Heron Therapeutics has a net margin of -22.52% compared to Synaptogenix's net margin of -2,153.97%. Synaptogenix's return on equity of -116.74% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-22.52%	-293.02%	-10.00%
Synaptogenix	-2,153.97%	-116.74%	-93.67%

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by insiders. Comparatively, 2.7% of Synaptogenix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Heron Therapeutics has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

Summary

Heron Therapeutics beats Synaptogenix on 12 of the 16 factors compared between the two stocks.

How does Synaptogenix compare to Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Synaptogenix (NASDAQ:TAOX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

Aldeyra Therapeutics presently has a consensus price target of $5.50, indicating a potential upside of 252.56%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Aldeyra Therapeutics is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aldeyra Therapeutics has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Aldeyra Therapeutics' return on equity of -53.14% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-53.14%	-34.94%
Synaptogenix	-2,153.97%	-116.74%	-93.67%

Synaptogenix has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A
Synaptogenix	$300K	85.66	-$28.74M	-$13.28	N/A

In the previous week, Synaptogenix had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 2 mentions for Synaptogenix and 1 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 1.89 beat Synaptogenix's score of 1.63 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aldeyra Therapeutics	Very Positive
Synaptogenix	Very Positive

Aldeyra Therapeutics has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 11.8% of Aldeyra Therapeutics shares are held by company insiders. Comparatively, 2.7% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Aldeyra Therapeutics beats Synaptogenix on 10 of the 15 factors compared between the two stocks.

How does Synaptogenix compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Synaptogenix (NASDAQ:TAOX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Verrica Pharmaceuticals has a net margin of -102.84% compared to Synaptogenix's net margin of -2,153.97%. Synaptogenix's return on equity of -116.74% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Synaptogenix	-2,153.97%	-116.74%	-93.67%

Verrica Pharmaceuticals has higher revenue and earnings than Synaptogenix. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.40	-$17.89M	-$1.67	N/A
Synaptogenix	$300K	85.66	-$28.74M	-$13.28	N/A

In the previous week, Verrica Pharmaceuticals and Verrica Pharmaceuticals both had 2 articles in the media. Synaptogenix's average media sentiment score of 1.63 beat Verrica Pharmaceuticals' score of 0.88 indicating that Synaptogenix is being referred to more favorably in the news media.

Company	Overall Sentiment
Verrica Pharmaceuticals	Positive
Synaptogenix	Very Positive

Verrica Pharmaceuticals currently has a consensus target price of $14.50, indicating a potential upside of 191.75%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Verrica Pharmaceuticals is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 2.7% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Verrica Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

Summary

Verrica Pharmaceuticals beats Synaptogenix on 11 of the 15 factors compared between the two stocks.

Get Synaptogenix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TAOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TAOX vs. The Competition

Export

Metric	Synaptogenix	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$26M	$11.89B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	-0.26	775.15	269.06	25.28
Price / Sales	85.66	743.86	602.43	91.76
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	1.22	11.60	12.91	6.24
Net Income	-$28.74M	$2.77B	$3.45B	$347.60M
7 Day Performance	2.08%	0.17%	1.12%	1.07%
1 Month Performance	-8.02%	0.35%	1.79%	1.03%
1 Year Performance	-62.57%	161.52%	67.69%	20.77%

Synaptogenix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TAOX Synaptogenix	0.8709 of 5 stars	$3.44 -1.1%	N/A	-63.6%	$26M	$300K	N/A	4	Earnings Report Gap Up
RFL Rafael	0.1718 of 5 stars	$1.94 -0.3%	N/A	+21.6%	$100.62M	$980K	N/A	20	Gap Up
ICCC ImmuCell	1.0856 of 5 stars	$11.04 -1.5%	N/A	+66.9%	$99.92M	$27.64M	N/A	70	News Coverage Earnings Report
HRTX Heron Therapeutics	1.9418 of 5 stars	$0.51 +3.6%	$2.50 +386.4%	-76.1%	$97.29M	$154.90M	N/A	300	Trending News Earnings Report Analyst Downgrade Analyst Revision
ALDX Aldeyra Therapeutics	3.442 of 5 stars	$1.54 -0.3%	$5.50 +258.3%	-73.2%	$92.59M	N/A	N/A	10	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TAOX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Synaptogenix (TAOX) Competitors

TAOX vs. RFL, ICCC, HRTX, ALDX, and VRCA

How does Synaptogenix compare to Rafael?

Summary

How does Synaptogenix compare to ImmuCell?

Summary

How does Synaptogenix compare to Heron Therapeutics?

Summary

How does Synaptogenix compare to Aldeyra Therapeutics?

Summary

How does Synaptogenix compare to Verrica Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAOX vs. The Competition

Synaptogenix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Synaptogenix (TAOX) Competitors

TAOX vs. RFL, ICCC, HRTX, ALDX, and VRCA

How does Synaptogenix compare to Rafael?

Does the media refer more to RFL or TAOX?

Do insiders & institutionals hold more shares of RFL or TAOX?

Which has higher earnings & valuation, RFL or TAOX?

Which has more risk & volatility, RFL or TAOX?

Do analysts rate RFL or TAOX?

Is RFL or TAOX more profitable?

Summary

How does Synaptogenix compare to ImmuCell?

Which has preferable valuation & earnings, ICCC or TAOX?

Do insiders and institutionals hold more shares of ICCC or TAOX?

Is ICCC or TAOX more profitable?

Which has more risk and volatility, ICCC or TAOX?

Do analysts rate ICCC or TAOX?

Does the media prefer ICCC or TAOX?

Summary

How does Synaptogenix compare to Heron Therapeutics?

Which has stronger earnings and valuation, HRTX or TAOX?

Does the media prefer HRTX or TAOX?

Do analysts rate HRTX or TAOX?

Is HRTX or TAOX more profitable?

Do institutionals & insiders hold more shares of HRTX or TAOX?

Which has more volatility and risk, HRTX or TAOX?

Summary

How does Synaptogenix compare to Aldeyra Therapeutics?

Do analysts prefer ALDX or TAOX?

Is ALDX or TAOX more profitable?

Which has better earnings & valuation, ALDX or TAOX?

Does the media refer more to ALDX or TAOX?

Which has more volatility and risk, ALDX or TAOX?

Do insiders and institutionals believe in ALDX or TAOX?

Summary

How does Synaptogenix compare to Verrica Pharmaceuticals?

Is VRCA or TAOX more profitable?

Which has higher valuation & earnings, VRCA or TAOX?

Does the media prefer VRCA or TAOX?

Do analysts prefer VRCA or TAOX?

Do institutionals & insiders believe in VRCA or TAOX?

Which has more volatility & risk, VRCA or TAOX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAOX vs. The Competition

Synaptogenix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools